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Abstract
Background
Urine from kidney transplant recipient has proven to be a viable source for donor DNA. How-
ever, an optimized protocol would be required to determine mis-matched donor HLA speci-
ficities in view of the scarcity of DNA obtained in some cases.
Methods
In this study, fresh early morning urine specimens were obtained from 155 kidney transplant
recipients with known donor HLA phenotype. DNA was extracted and typing of HLA-A, B
and DRB1 loci by polymerase chain reaction-specific sequence primers was performed
using tailor-made condition according to the concentration of extracted DNA.
Results
HLA typing of DNA extracted from urine revealed both recipient and donor HLA phenotypes,
allowing the deduction of the unknown donor HLA and hence the degree of HLA mis-match.
By adopting the modified procedures, mis-matched donor HLA phenotypes were success-
fully deduced in all of 35 tested urine samples at DNA quantities spanning the range of 620–
24,000 ng.
Conclusions
This urine-based method offers a promising and reliable non-invasive means for the identifi-
cation of mis-matched donor HLA antigens in kidney transplant recipients with unknown
donor HLA phenotype or otherwise inadequate donor information.
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Introduction
Approximately two-thirds of all kidney transplant recipients in Hong Kong underwent trans-
plantation overseas [1]. The lack of donor information hinders the investigation for donor-
specific antibody (DSA) and hampers the diagnosis and management of antibody-mediated
rejection. The information is also critical for the future selection of donors in patients who
undergo re-transplantation. Donors sharing HLA antigens with previously failed transplants,
even in the absence of DSA in the potential recipient, are avoided in some centres [2].
To tackle this problem, we previously reported a novel method to determine mismatched
donor HLA using fresh or formalin-fixed paraffin-embedded renal allograft tissue [3,4]. We
demonstrated that the allograft tissue expressed both donor and recipient HLA, and mis-
matched donor antigens could be deduced by subtracting the recipient’s HLA from the allo-
graft HLA. The information facilitates molecular diagnosis and patient management of
antibody mediate rejection, and enables appropriate selection of donor kidney for re-
transplantation.
Unlike obtaining patient HLA typing from the DNA extracted from peripheral blood sam-
ples, donor genetic information could only be obtained either from the kidney allograft or the
urine sample. In the present study, the feasibility of the same approach for deduction of mis-
matched donor HLA from recipients’ urine samples was evaluated. We aimed to circumvent
the need of deducing the donor HLA typing by the invasive allograft biopsy procedure and
develop a non-invasive and feasible protocol with superior practicality and sensitivity. We
launched a territory-wide study to investigate whether donor and recipient HLA could be
determined from urine samples of kidney transplant recipients. Urinary DNA chimerism was
found to be present following kidney transplantation [5]. A previous study by Srikantha et al.
has retrospectively tissue typed the recipient urine to determine mismatched donor HLA spec-
ificities; however, their results revealed that over 8% (3/34) urine samples failed to produce
adequate DNA for HLA typing without further resolution [6]. In the current study, with previ-
ous experience in modified PCR profile for allograft tissue [3,4], we are able to enhance the
detection rate of the mismatched HLA antigens from urine samples in low quantity of DNA
extracts.
The HLA typing data from the urine samples were expected to demonstrate a combination
of both recipient and donor HLA phenotypes. Mismatched donor HLA could thus be identi-
fied from the urine result and the recipient’s HLA data. We reason that the HLA typing
obtained from urine can avoid the invasive procedure of allograft kidney biopsy in obtaining
the same results. This methodology is thus a useful tool with the prospective application in the
maintenance of an accurate patient sensitization history especially when transplant performed
elsewhere or tissue typing were incomplete or less precise and may also abet post-transplant
immunological monitoring [7,8].
Materials and Methods
Patients
Between May and December in 2012, 155 fresh early morning urine samples were collected
from kidney transplant recipients with known donor-recipient HLA phenotypes from three
renal transplant centers in Hong Kong. The study was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/
HA HKW IRB) in accordance with the Declaration of Helsinki (Reference No. UW11-394).
Samples were collected after written informed consent was granted. If the participants are
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incompetent in giving consent, legal guardians or legally authorized representatives were con-
sented on the behalf of the participants. In order to minimize cellular degradation after collec-
tion, the urine samples were delivered to the HLA laboratory for DNA extraction within 4
hours. The extracted DNA from urine samples were kept at -30˚C for storage before further
testing.
DNA extraction
Fifty milliliter of fresh early morning urine was collected and centrifuged at 3,600 rpm for 30
minutes. The supernatant was discarded and the sediment was collected and washed with 1X
phosphate buffered saline and followed by centrifugation at full speed for 10 minutes. These
steps were repeated twice. DNA extraction was performed by automatic EZmag Genomic
DNA Whole Blood Kit (Texas BioGene Inc., Taiwan). The DNA extracts were kept at -30˚C
before use. Among the 155 DNA extracts, 35 representative samples covering all possible
ranges of DNA yields were further validated by polymerase chain reaction-specific sequence
primers (PCR-SSP) in which the composition of reaction mixture as well as the PCR profile
for each cycle were utilized as described in the manufacturer’s manual (Collaborative Trans-
plant Study, CTS, Department of Transplantation Immunology, University Clinic Heidelberg,
Germany) 4[4] but the number of PCR cycles selection against loci was tailor-made according
to the concentration of the DNA extracts as shown in Table 1. In brief, 25 μL and 50 μL DNA
samples were added to 69 μL and 138 μL 7.5% CTS PCR buffer for HLA-A and B loci respec-
tively, whereas 25 μL DNA was added to 69 μL 5.0% CTS master mix for HLA-DRB1 loci. In
addition, hot start JumpStart Taq DNA polymerase (Sigma, USA), 0.4 units/well was used to
enhance the sensitivity and specificity of the reaction. Ten microliters reaction mixtures were
dispensed into each tray well containing specific lyophilized primer mixes and then incubated
at 94˚C for 2 min to activate the JumpStart Taq DNA polymerase, followed by two subsequent
temperature cycling depend on various DNA yields at first cycle at 94˚C for 15 sec and 65˚C
for 1 min; and then second cycle at 94˚C for 15 sec, 61˚C for 50 sec and 72˚C for 30 sec. PCR
product is kept at 4˚C and were examined under gel electrophoresis through 2% agarose gel in
1X TAE.
Results
Among the 155 urine samples, 34.8% (54/155), 25.8% (40/155), 18.1% (28/155) and 21.3% (33/
155) yielded DNA amount>5,000 ng, 2,000–5,000 ng, 1,000–2,000 ng and 250–1,000 ng
respectively with purity (A260/A280) of 1.7–1.9. The time interval of specimen collection after
transplantation ranged from 349–7,125 days, 110–6,451 days, 14–3,850 days and 397–3,520
Table 1. Thermal cycling profile selection for samples with different DNA amount.
HLA loci Amount of DNA from urine samples (ng)
250–1,000 1,000–2,000 2,000–5,000 >5,000
Number of cycle in two-step PCR reactiona
(annealing temperature: 65˚C, 61˚C)
A 50, 50 20, 50 20, 40
B 30, 50 20, 40
DRB1
aAdoption of two step PCR reaction in order to enhance template quantity and end product amplification.
doi:10.1371/journal.pone.0166427.t001
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days respectively (Table 2). The data showed no correlation between DNA quantity in urine
samples and the time elapsed since transplantation.
Trials have been taken to adjust the number of cycles of PCR to obtain the optimal amplifi-
cation results in particular for those low DNA concentrations (data not shown). In the trials,
serial dilution of DNA from 1,000 to 125 ng was examined by employing the 100-cycle PCR
profile (i.e. by employing two subsequent 50-cycle PCR at annealing temperature 65˚C and
61˚C in order to enhance template quantity and end product amplification). The experiment
results revealed that the end-point sensitivity of the protocol could be up to 250 ng for HLA-A,
HLA-B and HLA-DRB1 loci. All urine samples can yield adequate DNA quantity and quality
required for HLA typing.
The impact of Escherichia coli colonization in the urine samples on this protocol was also
investigated; it was proved that the microbial DNA of E. coli caused no interference on the
accuracy of HLA typing of the patients. On the other hand, the microbial protein contaminant
could be minimized by repeat washing and centrifuging the urine sediment with phosphate
buffer as well as buffer washing during DNA extraction. The low protein contamination was
indicated by the purity range in A260/A280 of 1.7–1.9 in all DNA extracts.
To study the practicability of this protocol for deducing donor HLA typing from a wide
range of DNA level extracted from urine samples, 35 representative DNA samples that com-
prised 10, 10, 10 and 5 samples with total DNA yield in the ranges of 5,500–24,000 ng, 2,150–
4,900 ng, 1,200–1,900 ng and 620–950 ng respectively; were further tested by employing the
molecular protocol. The HLA phenotypes of the donor-recipient pairs were compared (Tables
3, 4, 5 and 6). All the HLA data from the samples successfully represented a composite of both
patient and donor HLA phenotypes (35/35). With no drop out, 31, 48 and 51 mismatched
donor HLA phenotypes bolded in Table 3 to Table 6 were detected at HLA-A, -B and -DRB1
loci, respectively. The PCR-SSP gel image of a representative sample was shown in Fig 1. Anti-
gen assignments were based on the reaction patterns provided by the manufacturer.
Discussion
The application of DNA extraction in urine sample and amplification by PCR-SSP in the diag-
nosis of acute rejection was reported by Zhang et al. [9,10]. In the current study, we used a
hot-start DNA polymerase to enhance the sensitivity and specificity of PCR and the amplifica-
tion profile was optimized and tailor-made according to different yield of DNA extracts as well
as HLA loci (Table 1). The correct allele-specific fragments could be distinguished from non-
specific PCR products by different band size as described in the manufacturer’s manual. Weak
false positive reactions due to addition amplification cycles were very rarely encountered, how-
ever, they could be interpreted as very rare HLA alleles with no impact on the final HLA phe-
notype interpretation if occur. In this study, 130 mismatched donor HLA antigens could be
deduced in PCR-SSP tested in 35 urine samples containing a wide range of DNA yield and
time interval after transplantation. The yield of DNA did not correlate with the time interval
after transplantation.
Table 2. Amount of DNA obtained from urine samples and the time interval of specimen collection after transplantation.
Amount of DNA from urine samples (ng) 250–1,000 1,000–2,000 2,000–5,000 >5,000
Percentage of samples 21.3% 18.1% 25.8% 34.8%
(33/155) (28/155) (40/155) (54/155)
Time after transplantation (days) 397–3,520 14–3,850 110–6,451 349–7,125
doi:10.1371/journal.pone.0166427.t002
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Although our results demonstrated correct mismatched antigens assignments of both
patient and donor HLA of 35 urine samples in our present cohort, the impact of preferential
PCR amplification of one allele over another in a heterozygous sample should be neglected.
For PCR-based HLA typing in which amplicons differ in size for different alleles, preferential
amplification of the shorter allele product may occur [11]. As the tested urine samples con-
tained both recipient and donor DNAs, the occurrence of preferential amplification may ham-
per the accurate HLA assignments. The donor-derived DNA may exist in minor proportion of
the urine DNA extract, thus preferential amplification of the major portion of the DNA allele
may occur. In such case, amplification of one or more alleles may fail leading to allele dropout.
To assess the performance of the modified protocol in order to rule out the occurrence of such
scenario, testing serial dilution of mixed DNAs from the donor and recipients would be desir-
able. However, due to the unavailability of donor DNA and limited DNA extract from urine of
each mismatched HLA typing pairs, such validation was not feasible in our current experimen-
tal setting. Further experiments will be conducted by artificially mixing two individual urine
DNA extracts.
The presence of DSA is important in diagnosing antibody-mediated rejection, predicting
graft survival and assessing response to rejection treatment. Serial monitoring of DSA allows
early intervention which may have significant impact on long-term allograft survival [7]. This
application is of particular concern in our local clinical setting as more than two-third of local
kidney transplant recipients received their grafts outside Hong Kong [12,13]. For this group of
patients the donor HLA phenotype is often not known, hence it was not possible to detect the
emergence of DSA after transplantation.
Table 3. HLA typing results of the five recipient-donor pairs and recipient urine samples with DNA yield 250 ng– 1,000 ng.
HLA
A B DR
Patient 1 (Whole blood) 2 / / 33 / 46 / 58 / 9 13 /
Donor (Whole blood) / 11 26 / 13 / 48 / 8 / / 15
Patient urine 2 11 26 33 13 46 48 58 8 9 13 15
Mismatches deduced / 11 26 / 13 / 48 / 8 / / 15
Patient 2 (Whole blood) 2 30 / / 13 46 / / 7 / 15 /
Donor (Whole blood) 2 / / / / 46 75 / / 9 15 /
Patient urine 2 30 / / 13 46 75 / 7 9 15 /
Mismatches deduced / / / / / / 75 / / 9 / /
Patient 3 (Whole blood) 24 / / / 35 51 / / 4 / 11 /
Donor (Whole blood) / 33 / / 35 / 61 / / 8 / 14
Patient urine 24 33 / / 35 51 61 / 4 8 11 14
Mismatches deduced / 33 / / / / 61 / / 8 / 14
Patient 4 (Whole blood) 2 / 33 / 17 46 / / / / 14 17
Donor (Whole blood) / 26 33 / 17 / 60 / 3 12 / /
Patient urine 2 26 33 / 17 46 60 / 3 12 14 17
Mismatches deduced / 26 / / / / 60 / 3 12 / /
Patient 5 (Whole blood) 2 11 / / / 46 48 / / 9 15 /
Donor (Whole blood) / 11 30 / 13 46 / / 7 9 / /
Patient urine 2 11 30 / 13 46 48 / 7 9 15 /
Mismatches deduced / / 30 / 13 / / / 7 / / /
Mismatched donor HLA phenotypes are shown in bold.
doi:10.1371/journal.pone.0166427.t003
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This study has demonstrated that this non-invasive assay has conceivable application for
the detection of mismatched donor HLA in kidney transplant recipients with unknown or
incomplete information of donor HLA phenotype. In addition, it can also utilize urine samples
Table 4. HLA typing results of the ten recipient-donor pairs and recipient urine samples with DNA yield between 1,000 ng and 2,000 ng.
HLA
A B DR
Patient 6 (Whole blood) 2 11 / / / 51 / / 9 15 / /
Donor (Whole blood) / / 24 / 13 51 / / 9 15 / /
Patient urine 2 11 24 / 13 51 / / 9 15 / /
Mismatches deduced / / 24 / 13 / / / / / / /
Patient 7 (Whole blood) 11 / / / / 75 / / / 12 14 /
Donor (Whole blood) / 24 26 / 46 75 / / 9 12 / /
Patient urine 11 24 26 / 46 75 / / 9 12 14 /
Mismatches deduced / 24 26 / 46 / / / 9 / / /
Patient 8 (Whole blood) 2 / 33 / / 40 / / / 9 / /
Donor (Whole blood) 2 24 / / 22 / 46 / 4 / 14 /
Patient urine 2 24 33 / 22 40 46 / 4 9 14 /
Mismatches deduced / 24 / / 22 / 46 / 4 / 14 /
Patient 9 (Whole blood) 2 11 / / 5 / / 40 / 4 9 /
Donor (Whole blood) / 11 33 / / 17 35 / 3 / / 12
Patient urine 2 11 33 / 5 17 35 40 3 4 9 12
Mismatches deduced / / 33 / / 17 35 / 3 / / 12
Patient 10 (Whole blood) 1 11 / / 37 / / 75 / 10 / 15
Donor (Whole blood) / / 24 29 / 39 60 60 4 / 13 /
Patient urine 1 11 24 29 37 39 60 75 4 10 13 15
Mismatches deduced / / 24 29 / 39 60 / 4 / 13 /
Patient 11 (Whole blood) 11 / / / / 60 75 / 9 / 12 /
Donor (Whole blood) 11 29 / / 7 60 / / 9 10 / /
Patient urine 11 29 / / 7 60 75 / 9 10 12 /
Mismatches deduced / 29 / / 7 / / / / 10 / /
Patient 12 (Whole blood) 2 11 / / / 58 62 / / 11 / 17
Donor (Whole blood) / 11 33 / 13 58 / / 9 / 14 /
Patient urine 2 11 33 / 13 58 62 / 9 11 14 17
Mismatches deduced / / 33 / 13 / / / 9 / 14 /
Patient 13 (Whole blood) 2 / 26 / / / 60 / 4 8 / /
Donor (Whole blood) 2 24 / / 39 46 / / 4 / 14 /
Patient urine 2 24 26 / 39 46 / / 4 8 14 /
Mismatches deduced / 24 / / 39 46 / / / / 14 /
Patient 14 (Whole blood) / 24 29 / 7 / 54 / 10 / 15 /
Donor (Whole blood) 11 / / 33 / 46 / / / 12 15 /
Patient urine 11 24 29 33 7 46 54 / 10 12 15 /
Mismatches deduced 11 / / 33 / 46 / / 12 / /
Patient 15 (Whole blood) 2 11 / / 46 / 62 / 4 12 / /
Donor (Whole blood) 2 11 / / / 54 / 75 4 / 15 /
Patient urine 2 11 / / / 54 / 75 / / 15 /
Mismatches deduced / / / / / 54 / 75 / / 15 /
Mismatched donor HLA phenotypes are shown in bold.
doi:10.1371/journal.pone.0166427.t004
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of transplant recipients to generate their respective historical HLA typing information of the
donor and thereby facilitating post-transplant immunological monitoring [8]. It is also useful
when the transplant was performed long ago when tissue typing was less precise or those
Table 5. HLA typing results of the ten recipient-donor pairs and recipient urine samples with DNA yield between 2,000 ng and 5,000 ng.
HLA
A B DR
Patient 16 (Whole blood) 11 24 / / 13 35 / / / / 14 15
Donor (Whole blood) 11 / / / / / 60 75 4 9 / /
Patient urine 11 24 / / 13 35 60 75 4 9 14 15
Mismatches deduced / / / / / / 60 75 4 9 / /
Patient 17 (Whole blood) / 29 33 / 7 58 / / 4 / 15 /
Donor (Whole blood) 11 / 33 / / 58 / / / 13 / 17
Patient urine 11 29 33 / / / / / 4 13 15 17
Mismatches deduced 11 / / / / / / / / 13 / 17
Patient 18 (Whole blood) 11 / / / / 55 65 / 11 / 15 /
Donor (Whole blood) 11 / / / 46 / / 75 / 12 15 /
Patient urine 11 / / / 46 55 65 75 11 12 15 /
Mismatches deduced / / / / 46 / / 75 / 12 / /
Patient 19 (Whole blood) 11 / 33 / / 51 58 / 9 / 13 /
Donor (Whole blood) 11 24 / / 48 51 / / 9 12 / /
Patient urine 11 24 33 / 48 51 58 / 9 12 13 /
Mismatches deduced / 24 / / 48 / / / / 12 / /
Patient 20 (Whole blood) / 24 33 / 54 58 / / / / 9 /
Donor (Whole blood) 2 / / / / / 60 71 4 8 / /
Patient urine 2 24 33 / 54 58 60 71 4 8 9 /
Mismatches deduced 2 / / / / / 60 71 4 8 / /
Patient 21 (Whole blood) 2 / / 26 8 / 38 / 4 / / 17
Donor (Whole blood) / 11 24 / / 13 / 58 / 14 15 /
Patient urine 2 11 24 26 8 13 38 58 4 14 15 17
Mismatches deduced / 11 24 / / 13 / 58 / 14 15 /
Patient 22 (Whole blood) / 11 / / / / / 75 / 12 / /
Donor (Whole blood) 2 / 33 / / 48 58 / 11 / 17 /
Patient urine 2 11 33 / / 48 58 75 11 12 17 /
Mismatches deduced 2 / 33 / / 48 58 / 11 / 17 /
Patient 23 (Whole blood) 2 / 24 / / 13 / 61 8 / 12 /
Donor (Whole blood) 2 11 / / / 13 46 / / 11 / 15
Patient urine 2 11 24 / / 13 46 61 8 11 12 15
Mismatches deduced / 11 / / / / 46 / / 11 / 15
Patient 24 (Whole blood) 24 / / / / 13 / 75 / 12 / 16
Donor (Whole blood) 24 33 / / / 13 44 / 7 / 15 /
Patient urine / 33 / / / 13 44 / 7 12 15 16
Mismatches deduced / 33 / / / / 44 / 7 / 15 /
Patient 25 (Whole blood) 2 11 / / 13 46 / / / 15 17 /
Donor (Whole blood) 2 11 / / / / 54 75 4 15 / /
Patient urine 2 11 / / 13 46 54 75 4 15 17 /
Mismatches deduced / / / / / / 54 75 4 / / /
Mismatched donor HLA phenotypes are shown in bold.
doi:10.1371/journal.pone.0166427.t005
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patients have failed graft function and required re-transplant. Without the precise donor’s
HLA typing, it is not feasible to identify DSA and assigning unacceptable mismatched antigens
for patients who require re-transplant, which may affect the survival of the new allograft. The
Table 6. HLA typing results of the ten recipient-donor pairs and recipient urine samples with DNA yield > 5,000 ng.
HLA
A B DR
Patient 26 (Whole blood) 24 33 / / 13 44 / / / / 13 15
Donor (Whole blood) 24 / / / 13 / 54 / 9 12 / /
Patient urine 24 33 / / 13 44 54 / 9 12 13 15
Mismatches deduced / / / / / / 54 / 9 12 / /
Patient 27 (Whole blood) 2 11 / / 13 56 / / / 15 / /
Donor (Whole blood) / 11 24 / 13 / 58 / 14 / 17 /
Patient urine 2 11 24 / 13 56 58 / 14 15 17 /
Mismatches deduced / / 24 / / / 58 / 14 / 17 /
Patient 28 (Whole blood) 11 / 30 / 13 46 / / 4 7 / /
Donor (Whole blood) 11 24 / / / 46 62 / 4 / 11 /
Patient urine 11 24 30 / 13 46 62 / 4 7 11 /
Mismatches deduced / 24 / / / / 62 / / / 11 /
Patient 29 (Whole blood) 2 11 / / / 60 / / 4 / 15 /
Donor (Whole blood) 2 11 / / 51 / 75 / 4 9 / /
Patient urine 2 11 / / 51 60 75 / 4 9 15 /
Mismatches deduced / / / / 51 / 75 / / 9 / /
Patient 30 (Whole blood) 11 / / / 27 54 / / 4 9 / /
Donor (Whole blood) 11 31 / / / / 55 60 4 / 14 /
Patient urine 11 31 / / 27 54 55 60 4 9 14 /
Mismatches deduced / 31 / / / / 55 60 / / 14 /
Patient 31 (Whole blood) / 24 / / / 56 60 / 9 / 13 /
Donor (Whole blood) 11 / / / 27 / 60 / 9 11 / /
Patient urine 11 24 / / 27 56 60 / 9 11 13 /
Mismatches deduced 11 / / / 27 / / / / 11 / /
Patient 32 (Whole blood) 11 24 / / / 58 60 / 4 / 13 /
Donor (Whole blood) 11 / / / 46 / / 62 4 9 / /
Patient urine 11 24 / / 46 58 60 62 4 9 13 /
Mismatches deduced / / / / 46 / / 62 / 9 / /
Patient 33 (Whole blood) 11 33 / / 55 58 / / / 12 / 17
Donor (Whole blood) 11 33 / / / 58 75 / 9 / 13 /
Patient urine 11 33 / / 55 58 75 / 9 12 13 17
Mismatches deduced / / / / / / 75 / 9 / 13 /
Patient 34 (Whole blood) 2 31 / / 44 51 / / 7 / 17 /
Donor (Whole blood) 2 / 33 / 44 / 62 / 7 11 / /
Patient urine 2 31 33 / 44 51 62 / 7 11 17 /
Mismatches deduced / / 33 / / / 62 / / 11 / /
Patient 35 (Whole blood) 2 11 / / 46 75 / / 9 11 / /
Donor (Whole blood) 2 / / / 46 / / / 9 / 12 /
Patient urine 2 11 / / 46 75 / / 9 11 12 /
Mismatches deduced / / / / / / / / / / 12 /
Mismatched donor HLA phenotypes are shown in bold.
doi:10.1371/journal.pone.0166427.t006
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application of DNA extraction in urine samples demonstrated in our current protocol offers a
non-invasive alternative with superior sensitivity and circumvents the necessity of an invasive
allograft biopsy procedure. This attractive diagnostic method would be welcomed by renal
physician for management of post-transplant renal patients with insufficient donor informa-
tion who underwent transplantation overseas.
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